Treatment with the Gonadotropin-Releasinghormone Agonist Buserelin to Protect Spermatogenesis against Cytotoxic Treatment in Young Men/Behandlung zum Schutz der Spermatogenese bei cytotoxischer Therapie mit dem Gonadotropin-Hormon Agonisten Buserelin
- 24 April 2009
- journal article
- Published by Hindawi Limited in Andrologia
- Vol. 21 (3) , 265-270
- https://doi.org/10.1111/j.1439-0272.1989.tb02407.x
Abstract
No abstract availableKeywords
This publication has 11 references indexed in Scilit:
- Protection of Spermatogenesis During Cancer ChemotherapyArchives of Andrology, 1987
- Attempted Protection of Spermatogenesis From Single Doses of Gamma-Irradiation in the Androgen Pretreated RatArchives of Andrology, 1987
- Hormonal effects of GnRH agonist in the human male: An approach to male contraception using combined androgen and GnRH agonist treatmentJournal of Steroid Biochemistry, 1985
- Does constant infusion of gonadotropin-releasing hormone agonist lead to greater suppression of gonadal function in man than its intermittent administration?Fertility and Sterility, 1985
- Testicular Histology After Prolonged Treatment with a Gonadotropin-Releasing Hormone AnalogueJournal of Urology, 1985
- PROTECTION FROM CYCLOPHOSPHAMIDE-INDUCED TESTICULAR DAMAGE WITH AN ANALOGUE OF GONADOTROPIN-RELEASING HORMONEThe Lancet, 1981
- Gonadal Function in Males Treated with Cyclophosphamide for Nephrotic SyndromeFertility and Sterility, 1979
- RETURN OF SPERMATOGENESIS AFTER STOPPING CYCLOPHOSPHAMIDE THERAPYThe Lancet, 1975
- Effect of Human Urinary FSH and LH on the Recovery of Spermatogenesis in Hypophysectomized PatientsJournal of Clinical Endocrinology & Metabolism, 1971
- Regulation by FSH and ICSH(LH) of Reproductive Function in the Immature Male RatEndocrinology, 1969